GUELPH, ON, June 14 /CNW/ - BIOREM Inc. ("Biorem" or "the Company") (TSX-V: BRM) today announced that it has received four new orders totaling $1.3 million from customers in the United States for its biological based emission control systems.
"While our main focus is on applying our technology in new markets, we will continue to maintain our leadership position in our core odor control business. These orders reflect that we are maintaining momentum in booking new orders for our systems and now benefiting from the U.S. economic recovery and resumed municipal capital spending," said Peter Bruijns, President and CEO.
The systems ordered consist of two custom-designed biofilters and one modular biofilter utilizing Biorem's proprietary Biosorbens(R) media to be installed at wastewater treatment plants. One system will treat 8,000 cfm of air produced from equalization tanks, the second much larger installation will treat 21,000 cfm of air produced from sludge holding tanks and a dewatering facility, while the third system will treat hydrogen sulfide concentrations from a headworks building. The fourth system is a multi-stage biotrickling filter designed to treat hydrogen sulfide at an average concentration of 50 ppm produced at a wastewater treatment facility's lift stations.
About BIOREM Inc.
Biorem is a leading clean technology company that designs, manufactures and distributes a comprehensive line of high-efficiency air emissions control systems used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). With sales and manufacturing offices across the continent, a dedicated research facility, a worldwide sales representative network and over 600 installed systems worldwide, Biorem not only offers state-of-the-art technology-based products but also peace of mind for municipalities, industrial companies and their surrounding communities. Additional information on Biorem is available on our website at www.biorem.biz.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking statements based on current expectations. These forward-looking statements contain various risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Risks and uncertainties about the Company's business are more fully discussed in the disclosure materials, financial statements and MD&A filed with the securities regulatory authorities in Canada on www.sedar.com.
"Bookings" and "Backlog" do not have any standardized meaning prescribed by Canadian generally accepted accounting principles ("GAAP") and may not be comparable to measures presented by other companies. Bookings and Backlog are non-GAAP measures that the Company uses to evaluate its sales performance. Bookings are those binding contracts that the Company enters into with a third party for the delivery of our products or services. As Bookings are received, the contract value (before any associated sales taxes) is included in the Backlog. The Backlog is reduced by the revenue that is recognized on each project and then adjusted for any currency changes.
SOURCE BIOREM Inc.
For further information: For further information: Ed Corbett, Chief Financial Officer, BIOREM Technologies Inc., email@example.com, Tel: (519) 767-9100 x275; James Smith, Investor Relations, The Equicom Group Inc., firstname.lastname@example.org, Tel: (416) 815-0700 x229